Lung Cancer Therapy Targeting Histone Methylation: Opportunities and Challenges.
Comput Struct Biotechnol J
; 16: 211-223, 2018.
Article
en En
| MEDLINE
| ID: mdl-30002791
ALK, anaplastic lymphoma kinase; DUSP3, dual-specificity phosphatase 3; EMT, epithelial-to-mesenchymal transition; Elk1, ETS-domain containing protein; HDAC, histone deacetylase; Histone demethylase; Histone demethylation; Histone methylation; Histone methyltransferase; IHC, immunohistochemistry; Inhibitors; KDMs, lysine demethylases; KLF2, Kruppel-like factor 2; KMTs, lysine methyltransferases; LSDs, lysine specific demethylases; Lung cancer; MEP50, methylosome protein 50; NSCLC, non-small cell lung cancer; PAD4, peptidylarginine deiminase 4; PCNA, proliferating cell nuclear antigen; PDX, patient-derived xenografts; PRC2, polycomb repressive complex 2; PRMTs, protein arginine methyltrasferases; PTMs, posttranslational modifications; SAH, S-adenosyl-L-homocysteine; SAM, S-adenosyl-L-methionine; SCLC, small cell lung cancer; TIMP3, tissue inhibitor of metalloproteinase 3
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Idioma:
En
Revista:
Comput Struct Biotechnol J
Año:
2018
Tipo del documento:
Article
País de afiliación:
China
Pais de publicación:
Países Bajos